452 related articles for article (PubMed ID: 21455605)
1. A novel mechanism of dasatinib-induced apoptosis in chronic myeloid leukemia; ceramide synthase and ceramide clearance genes.
Gencer EB; Ural AU; Avcu F; Baran Y
Ann Hematol; 2011 Nov; 90(11):1265-75. PubMed ID: 21455605
[TBL] [Abstract][Full Text] [Related]
2. Resveratrol triggers apoptosis through regulating ceramide metabolizing genes in human K562 chronic myeloid leukemia cells.
Kartal M; Saydam G; Sahin F; Baran Y
Nutr Cancer; 2011; 63(4):637-44. PubMed ID: 21500096
[TBL] [Abstract][Full Text] [Related]
3. Roles of ceramide synthase and ceramide clearence genes in nilotinib-induced cell death in chronic myeloid leukemia cells.
Camgoz A; Gencer EB; Ural AU; Avcu F; Baran Y
Leuk Lymphoma; 2011 Aug; 52(8):1574-84. PubMed ID: 21756066
[TBL] [Abstract][Full Text] [Related]
4. Glucosylceramide synthase inhibitor PDMP sensitizes chronic myeloid leukemia T315I mutant to Bcr-Abl inhibitor and cooperatively induces glycogen synthase kinase-3-regulated apoptosis.
Huang WC; Tsai CC; Chen CL; Chen TY; Chen YP; Lin YS; Lu PJ; Lin CM; Wang SH; Tsao CW; Wang CY; Cheng YL; Hsieh CY; Tseng PC; Lin CF
FASEB J; 2011 Oct; 25(10):3661-73. PubMed ID: 21705667
[TBL] [Abstract][Full Text] [Related]
5. Bioactive sphingolipids in docetaxel-induced apoptosis in human prostate cancer cells.
Bassoy EY; Baran Y
Biomed Pharmacother; 2012 Mar; 66(2):103-10. PubMed ID: 22326625
[TBL] [Abstract][Full Text] [Related]
6. The roles of bioactive sphingolipids in resveratrol-induced apoptosis in HL60: acute myeloid leukemia cells.
Cakir Z; Saydam G; Sahin F; Baran Y
J Cancer Res Clin Oncol; 2011 Feb; 137(2):279-86. PubMed ID: 20401667
[TBL] [Abstract][Full Text] [Related]
7. The roles of antiapoptotic sphingosine kinase-1 and glucosylceramide genes in drug induced cell death of MCF-7 breast cancer cells.
Gucluler G; Piskin O; Baran Y
J BUON; 2011; 16(4):646-51. PubMed ID: 22331716
[TBL] [Abstract][Full Text] [Related]
8. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
9. Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation.
Baran Y; Bielawski J; Gunduz U; Ogretmen B
J Cancer Res Clin Oncol; 2011 Oct; 137(10):1535-44. PubMed ID: 21833718
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells.
Okabe S; Tauchi T; Ohyashiki K
Clin Cancer Res; 2008 Oct; 14(19):6181-6. PubMed ID: 18829496
[TBL] [Abstract][Full Text] [Related]
11. Increased killing of SCCVII squamous cell carcinoma cells after the combination of Pc 4 photodynamic therapy and dasatinib is associated with enhanced caspase-3 activity and ceramide synthase 1 upregulation.
Separovic D; Breen P; Boppana NB; Van Buren E; Joseph N; Kraveka JM; Rahmaniyan M; Li L; Gudz TI; Bielawska A; Bai A; Bielawski J; Pierce JS; Korbelik M
Int J Oncol; 2013 Dec; 43(6):2064-72. PubMed ID: 24126464
[TBL] [Abstract][Full Text] [Related]
12. In vitro anti-leukaemia activity of sphingosine kinase inhibitor.
Ricci C; Onida F; Servida F; Radaelli F; Saporiti G; Todoerti K; Deliliers GL; Ghidoni R
Br J Haematol; 2009 Feb; 144(3):350-7. PubMed ID: 19036099
[TBL] [Abstract][Full Text] [Related]
13. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells.
Baran Y; Salas A; Senkal CE; Gunduz U; Bielawski J; Obeid LM; Ogretmen B
J Biol Chem; 2007 Apr; 282(15):10922-34. PubMed ID: 17303574
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of targeting ceramide/glucosylceramide pathway in cancer.
Kartal Yandım M; Apohan E; Baran Y
Cancer Chemother Pharmacol; 2013 Jan; 71(1):13-20. PubMed ID: 23073611
[TBL] [Abstract][Full Text] [Related]
16. Toward therapeutic effects evaluation of chronic myeloid leukemia drug: electrochemical platform for caspase-3 activity sensing.
Zhou S; Zheng T; Chen Y; Zhang J; Li L; Lu F; Zhu JJ
Biosens Bioelectron; 2014 Nov; 61():648-54. PubMed ID: 24976045
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib: BMS 354825.
Drugs R D; 2006; 7(2):129-32. PubMed ID: 16542059
[TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein is implicated in the inhibition of ceramide-induced apoptosis in TF-1 acute myeloid leukemia cells by modulation of the glucosylceramide synthase pathway.
Turzanski J; Grundy M; Shang S; Russell N; Pallis M
Exp Hematol; 2005 Jan; 33(1):62-72. PubMed ID: 15661399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
